An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 May 2019
Price : $35 *
At a glance
- Drugs Netakimab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms PATERA
- Sponsors Biocad
- 23 May 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Dec 2018 Status changed from not yet recruiting to recruiting.
- 22 Aug 2018 Planned primary completion date changed from 31 Dec 2019 to 30 Apr 2020.